Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Ifosfamide, Vincristine Combination

This is a multi-drug chemotherapy combination used primarily in the treatment of sarcomas, particularly Ewing sarcoma. The combination is administered in alternating cycles, with different drugs given at different points in the treatment protocol.

Treatment Regimens

The drugs are typically administered in specific combinations:

• VDC (Vincristine, Doxorubicin, Cyclophosphamide) alternating with
• IE (Ifosfamide, Etoposide)
• Sometimes with the addition of dactinomycin (actinomycin D)

These drugs work together to target rapidly dividing cancer cells through different mechanisms of action. The combination is intensive and associated with significant toxicity, but has shown improved outcomes in certain sarcoma types.

Dosing Information

Typical dosing schedules include:

VDC portion:

• Vincristine: 1.5-2 mg/m² IV on day 1
• Doxorubicin: 75-80 mg/m² IV on day 1
• Cyclophosphamide: 1200 mg/m² IV on day 1

IE portion:

• Ifosfamide: 1800-9000 mg/m² IV (often divided over 5 days)
• Etoposide: 100-450 mg/m² IV (often divided over 5 days)

When dactinomycin is included:

• Dactinomycin: 1.25-1.5 mg/m² IV

Clinical Evidence

The Euro-EWING99-R1 trial and other studies have investigated various combinations of these drugs for treating Ewing sarcoma. The evidence suggests that interval-compressed alternating cycles (every 14 days versus every 21 days) may improve outcomes in localized Ewing sarcoma.

In one study with a median follow-up of 110 months, 5-year overall survival and event-free survival were 72% and 66%, respectively. Another study showed actuarial 5-year event-free survival and overall survival rates of 42% and 45%, respectively.

Toxicity

This combination regimen is associated with significant toxicity, including:

• Febrile neutropenia (reported in 13-49% of cycles)
• Thrombocytopenia
• Cardiac dysfunction
• Renal toxicity
• Hemorrhagic cystitis (preventable with mesna)

The toxicity profile differs between adult and pediatric patients, with pediatric patients generally requiring more supportive care including blood product transfusions.